StephanieJoiLeeMD

Oncology • Seattle, WA

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Are you Dr. Lee?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1959 NE Pacific St
Seattle, WA 98195
Phone+1 206-598-4615

Fax+1 206-606-1025

Summary

Dr. Stephanie Lee, MD is an oncologist in Seattle, Washington. She is currently licensed to practice medicine in Washington, Massachusetts, and California. She is affiliated with UW Medicine/University of Washington Medical Center, Fred Hutch Cancer Center, and UW Medicine/Harborview Medical Center.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996
Stanford University School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1991 - Present
WA State Medical License 2005 - 2026
MA State Medical License 1993 - 2006
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2009

Clinical Trials

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Start of enrollment: 2001 Jan 01
Completed
Phase 3
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Start of enrollment: 2007 Mar 01
Completed
Phase 3
Improving Outcomes Assessment in Chronic GVHD Start of enrollment: 2007 Sep 01
Active, not recruiting
Exercise and Stress Management Post Autologous and Allogeneic Transplant (BMT CTN 0902) Start of enrollment: 2011 Jan 01
Completed
Not Applicable
Chronic GVHD Response Measures Validation Start of enrollment: 2013 Jun 01
Active, not recruiting
Tocilizumab for Chronic Graft-versus-Host Disease Treatment Start of enrollment: 2016 Feb 01
Withdrawn
Phase 2
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2015 Nov 12
Completed
Phase 2
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study Start of enrollment: 2020 Jun 29
Recruiting
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant Start of enrollment: 2021 May 14
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Racial and socioeconomic status diversity and GVHD outcomes.
Nosha Farhadfar, Stephanie J Lee
Blood Advances. 2025-02-11
Longitudinal Tear Cytokine Biomarkers: An Analysis from the Close Assessment and Testing for Chronic Graft-Versus-Host Disease (CATCH) Protocol.
Najla El Jurdi, Betty K Hamilton, Joseph A Pidala, Lynn Onstad, Christine Mun
Transplantation and Cellular Therapy. 2025-02-07
Factors associated with early quality of life response to palliative care during hematopoietic cell transplantation.
Richard A Newcomb, Hermioni L Amonoo, Alison R Kavanaugh, Kristin C Wharton, Michaela Rowland
Blood Advances. 2025-02-05

Press Mentions

Combating Burnout as a Single Working ParentJune 29th, 2021
Seattle Cancer Care Alliance to Present New Research at 62nd Annual Meeting of the American Society of HematologyDecember 4th, 2020
ASH Announces Executive Committee Election Results, New Clinical Practice Guidelines, and MoreNovember 5th, 2020
Join now to see all